Literature DB >> 17984831

The immunobiology of corneal transplantation.

Keryn A Williams1, Douglas J Coster.   

Abstract

Corneal allotransplantation is highly successful in the short term, but much less successful in the longer term. Many corneal grafts in recipients with corneal neovascularization or the sequelae of ocular inflammation undergo irreversible rejection, despite topical immunosuppression with glucocorticosteroids. Sensitization to cornea-derived alloantigen proceeds by both direct and indirect routes, but the anatomic location of sensitization remains unclear. Multiple and redundant mechanisms operate in the effector phase of corneal graft rejection, which is largely cell-mediated rather than antibody-mediated. Human leukocyte antigen matching may improve outcomes in high-risk patients but systemic immunosuppression is frequently ineffective and is seldom used.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984831     DOI: 10.1097/01.tp.0000285489.91595.13

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  25 in total

1.  [Immunological graft rejection after autologous contralateral keratoplasty].

Authors:  S Schmidt; M P Holzer; R Khoramnia; G U Auffarth
Journal:  Ophthalmologe       Date:  2012-10       Impact factor: 1.059

Review 2.  Xenotransplantation--the future of corneal transplantation?

Authors:  Hidetaka Hara; David K C Cooper
Journal:  Cornea       Date:  2011-04       Impact factor: 2.651

3.  Corneal graft rejection in African Americans at Howard University Hospital.

Authors:  Larry Ferdinand; Vanessa Ngakeng; Robert A Copeland
Journal:  Saudi J Ophthalmol       Date:  2011-04-30

Review 4.  Management of high-risk corneal transplantation.

Authors:  Antonio Di Zazzo; Ahmad Kheirkhah; Tulio B Abud; Sunali Goyal; Reza Dana
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

Review 5.  Immune privilege of corneal allografts.

Authors:  Jerry Y Niederkorn; D Frank P Larkin
Journal:  Ocul Immunol Inflamm       Date:  2010-06       Impact factor: 3.070

Review 6.  Therapeutic approaches for induction of tolerance and immune quiescence in corneal allotransplantation.

Authors:  Maryam Tahvildari; Afsaneh Amouzegar; William Foulsham; Reza Dana
Journal:  Cell Mol Life Sci       Date:  2018-01-06       Impact factor: 9.261

7.  Initial in vitro investigation of the human immune response to corneal cells from genetically engineered pigs.

Authors:  Hidetaka Hara; Naoko Koike; Cassandra Long; Jordan Piluek; Danny S Roh; Nirmala SundarRaj; James L Funderburgh; Yoshiaki Mizuguchi; Kumiko Isse; Carol J Phelps; Suyapa F Ball; David L Ayares; David K C Cooper
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-15       Impact factor: 4.799

8.  Inhibitory effects of topical cyclosporine A 0.05% on immune-mediated corneal neovascularization in rabbits.

Authors:  Yasin Yücel Bucak; Mesut Erdurmus; Elçin Hakan Terzi; Aysel Kükner; Serdal Çelebi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-09-19       Impact factor: 3.117

9.  In vivo downregulation of innate and adaptive immune responses in corneal allograft rejection by HC-HA/PTX3 complex purified from amniotic membrane.

Authors:  Hua He; Yaohong Tan; Stephanie Duffort; Victor L Perez; Scheffer C G Tseng
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-19       Impact factor: 4.799

10.  Stem cell therapy restores transparency to defective murine corneas.

Authors:  Yiqin Du; Eric C Carlson; Martha L Funderburgh; David E Birk; Eric Pearlman; Naxin Guo; Winston W-Y Kao; James L Funderburgh
Journal:  Stem Cells       Date:  2009-07       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.